(Q37139737)

18 August 2017

1 reference

title

Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections (English)

1 reference

18 August 2017

1

Lily P H Yang

1 reference

18 August 2017

Susan J Keam

2

1 reference

18 August 2017

publication date

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

68

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

855-873

1 reference

High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases

18 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200868060-00008

Fusidic acid resistance in Staphylococcus aureus

21 January 2018

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection

1 reference

12 December 2020

Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for gram-positive cocci

1 reference

12 December 2020

Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case-control study

1 reference

12 December 2020

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement

1 reference

12 December 2020

Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia

1 reference

12 December 2020

Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial

1 reference

12 December 2020

Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial

1 reference

12 December 2020

Oral beta-lactams applied to uncomplicated infections of skin and skin structures

1 reference

12 December 2020

Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods

1 reference

12 December 2020

Disk diffusion interpretive criteria for fusidic acid susceptibility testing of staphylococci by the National Committee for Clinical Laboratory Standards method

1 reference

12 December 2020

Management of community-associated methicillin-resistant Staphylococcus aureus infections in children

1 reference

12 December 2020

Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance

1 reference

12 December 2020

Staphylococcal skin infections in children: rational drug therapy recommendations

1 reference

12 December 2020

Diagnosis and treatment of impetigo.

1 reference

12 December 2020

Common bacterial skin infections.

1 reference

12 December 2020

Molecular basis of fusB-mediated resistance to fusidic acid in Staphylococcus aureus.

1 reference

12 December 2020

A guide to antibiotic resistance in bacterial skin infections

1 reference

12 December 2020

Fusidic acid-resistant Staphylococcus aureus (FRSA) carriage in patients with atopic eczema and pattern of prior topical fusidic acid use

1 reference

12 December 2020

Interventions for impetigo

1 reference

12 December 2020

Topical mupirocin for eradication of MRSA colonization with mupirocin-resistant strains

1 reference

12 December 2020

Bacterial skin infections in the elderly: diagnosis and treatment

1 reference

12 December 2020

The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice

1 reference

12 December 2020

Genetic basis of resistance to fusidic acid in staphylococci.

1 reference

12 December 2020

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

1 reference

12 December 2020

Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic

1 reference

12 December 2020

Susceptibility of skin and soft-tissue isolates of Staphylococcus aureus and Streptococcus pyogenes to topical antibiotics: indications of clonal spread of fusidic acid-resistant Staphylococcus aureus.

1 reference

12 December 2020

Use of mupirocin ointment in the treatment of secondarily infected dermatoses

1 reference

12 December 2020

Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes

1 reference

12 December 2020

Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema

1 reference

12 December 2020

Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes

1 reference

12 December 2020

Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin

1 reference

12 December 2020

Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci

1 reference

12 December 2020

Treatment for impetigo

1 reference

12 December 2020

Status report on antibiotic resistance: implications for the dermatologist

1 reference

12 December 2020

Characterization of a variant of vga(A) conferring resistance to streptogramin A and related compounds

1 reference

12 December 2020

Fusidic acid cream for impetigo. Judicious use is advisable

1 reference

12 December 2020

Mupirocin resistance in staphylococci: development and transfer of isoleucyl-tRNA synthetase-mediated resistance in vitro.

1 reference

12 December 2020

High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients

1 reference

12 December 2020

Fusidic acid cream for impetigo. Fusidic acid should be used with restraint

1 reference

12 December 2020

Interpretive criteria for testing susceptibility of staphylococci to mupirocin

1 reference

12 December 2020

Antimicrobial agents are societal drugs: how should this influence prescribing?

1 reference

12 December 2020

Selection of retapamulin, a novel pleuromutilin for topical use

1 reference

12 December 2020

Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study

1 reference

12 December 2020

Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners

1 reference

12 December 2020

Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin

1 reference

12 December 2020

Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment

1 reference

12 December 2020

Comparative in vitro activities of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium spp., including 117 P. acnes isolates

1 reference

12 December 2020

How do you improve compliance?

1 reference

12 December 2020

Mupirocin resistance in staphylococci

1 reference

12 December 2020

Interpretive criteria for mupirocin susceptibility testing of Staphylococcus spp. using CLSI guidelines

1 reference

12 December 2020

In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections.

1 reference

12 December 2020

10.2165/00003495-200868060-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

18 August 2017

1050195106

0 references

1 reference